Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
Would a BRAF V600E mutation affect your decision to give adjuvant therapy in a patient with lung cancer?
Related Questions
How do you handle Grade 3-4 standard infusion reactions with Amivantamab?
In light of recent retrospective data from France on EGFR TKIs use with PPIs showing negative outcomes in NSCLC patients would you consider discontinuing PPIs or changing PPIs to H2 inhibitors?
In light of the FLAURA2 data, which patients would you recommend upfront treatment with chemotherapy + osimertinib rather than osimertinib monotherapy?
In patients with EGFR mutant L858R stage III NSCLC who are unresectable due to multistation N2 disease, would you consider upfront osimertinib over definitive intent CCRT?
Would you consider stopping EGFR inhibitor in EGFR mutant NSCLC on a patient who was NED for >5 years?
Is there a role for nintedanib in the management of patients with radiation-induced pulmonary fibrosis?
Would you offer consolidative durvalumab after chemoRT for an isolated mediastinal recurrence of NSCLC that occurred during adjuvant pembrolizumab given for the initial lung cancer?
How would you manage a patient with radiation pneumonitis who remains symptomatic on steroids?
How would you treat a patient with progressive ALK (+) NSCLC that has MET Exon 14 deletion upon repeat molecular testing on metastatic site?
How do you treat Stage IIIC T4N3 NSCLC?
